Pharmaceutical major Novartis has entered into an agreement with fellow Switzerland-based food giant Nestle to acquire 74 million, or around 25%, of the outstanding shares of its majority-owned subsidiary Alcon, at a price of $143.18 each, for a total of about $11.0 billion.
The food group would retain 52% of Alcon but, under put and call option rights, which commence on January 1, 2010 and end July 31, 2011, Novartis can buy the remaining Nestle holding at a fixed cost of $181 a share, or a 20.5% premium to the then prevailing market price, for a total of some $28.0 billion. The two firms are already well-versed in buying from each other, since the drugmaker last year sold both its Novartis Medical Nutrition and Gerber baby foods businesses to Nestle for a total of around $8.0 billion and its Novartis Nutrition operation for $2.5 billion in 2006.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
| Headless Content Management with Blaze